Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of the American Society of Nephrology

• Publication date

  2004-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.ASN.0000141016.20133.33PMID 15466262
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.

  2003cited by this paper
• Human Calcium-sensing Receptor Gene

  2002cited by this paper
• The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism.

  2002cited by this paper
• Reversal of Secondary Hyperparathyroidism by Phosphate Restriction Restores Parathyroid Calcium‐Sensing Receptor Expression and Function

  2002cited by this paper
• Calcium Receptors as Novel Drug Targets

  2002cited by this paper
• Differentiation of human parathyroid cells in culture.

  2001cited by this paper
• p21WAF1 and TGF-α mediate parathyroid growth arrest by vitamin D and high calcium

  2001cited by this paper
• p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium.

  2001cited by this paper
• Extracellular calcium sensing and extracellular calcium signaling.

  2001cited by this paper
• Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice.

  2001cited by this paper
• Human parathyroid cell proliferation in response to calcium, NPS R‐467, calcitriol and phosphate

  2001cited by this paper
• Parathyroid hyperplasia in uremic rats precedes down-regulation of the calcium receptor.

  2001cited by this paper
• Cellular "sensing" of extracellular calcium (Ca(2+)(o)): emerging roles in regulating diverse physiological functions.

  2000cited by this paper
• Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism.

  2000cited by this paper
• A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism.

  2000influential reference
• Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism.

  2000cited by this paper
• Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats.

  2000cited by this paper
• How should anaemia be managed in pre-dialysis patients?

  1999cited by this paper
• Rescue of the Skeletal Phenotype of Vitamin D Receptor-Ablated Mice in the Setting of Normal Mineral Ion Homeostasis: Formal Histomorphometric and Biomechanical Analyses1.

  1999cited by this paper
• The role of calcium-sensing receptor abnormality in the pathogenesis of secondary hyperparathyroidism.

  1999cited by this paper
• Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: role of dietary phosphate.

  1999cited by this paper
• NPS R-568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium.

  1999cited by this paper
• Calcimimetics with potent and selective activity on the parathyroid calcium receptor.

  1998cited by this paper
• Monoclonal Antibodies Against Synthetic Peptides Corresponding to the Extracellular Domain of the Human Ca2+ Receptor: Characterization and Use in Studying Concanavalin A Inhibition

  1997cited by this paper
• Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism.

  1997cited by this paper
• The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor.

  1997influential reference
• Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism.

  1997cited by this paper
• The parathyroid calcium receptor: a novel therapeutic target for treating hyperparathyroidism

  1996cited by this paper
• Rat calcium-sensing receptor is regulated by vitamin D but not by calcium.

  1996cited by this paper
• The calcium-sensing receptor: a window into the physiology and pathophysiology of mineral ion metabolism.

  1996cited by this paper
• Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism.

  1996cited by this paper
• Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro

  1996cited by this paper
• Calcium receptor messenger ribonucleic acid levels in the parathyroid glands and kidney of vitamin D-deficient rats are not regulated by plasma calcium or 1,25-dihydroxyvitamin D3.

  1995cited by this paper
• A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism

  1995cited by this paper

• Evocalcet improved the PTH-calcium setpoint and suppressed parathyroid proliferation in mice model of primary hyperparathyroidism.

  2026cites this paper
• Effects of evocalcet on parathyroid calcium‐sensing receptor and vitamin D receptor expression in uremic rats

  2023cites this paper
• Etelcalcetide Inhibits the Progression of Left Atrial Volume Index Compared to Alfacalcidol in Hemodialysis Patients

  2023cites this paper
• Effect of etelcalcetide versus alfacalcidol on left ventricular function and feature-tracking cardiac magnetic resonance imaging in hemodialysis—a post-hoc analysis of a randomized, controlled trial

  2023cites this paper
• Rescue of High Glucose Impairment of Cultured Human Osteoblasts Using Cinacalcet and Parathyroid Hormone

  2023cites this paper
• Extracellular Ca2+ aggravates IgE-induced allergic reaction in mast cells through GPRC6A, a novel family C G-protein-coupled receptor.

  2022cites this paper
• Biology of the extracellular calcium-sensing receptor

  2020cites this paper
• Early Response of the Parathyroid Gland to Withdrawal of a Calcimimetic Compound in Uremic Rats.

  2020cites this paper
• Calcium-sensing receptor in physiology and in calcitropic and non-calcitropic diseases

  2019cites this paper
• The Different Facets of Extracellular Calcium Sensors: Old and New Concepts in Calcium-Sensing Receptor Signalling and Pharmacology

  2018cites this paper
• The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases

  2018cites this paper
• Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients

  2018cites this paper
• Cancer and Tumor Review

  2018cites this paper
• Calcimimetic and calcilytic therapies for inherited disorders of the calcium‐sensing receptor signalling pathway

  2018cites this paper
• Secondary Hyperparathyroidism: Pathogenesis and Latest Treatment

  2018cites this paper
• Effects of preoperative cinacalcet hydrochloride treatment on the operative course of parathyroidectomy and pathological changes in resected parathyroid glands

  2017cites this paper
• Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease.

  2017cites this paper
• Vitamin D and Parathyroid Hormone Regulation in Chronic Kidney Disease

  2016cites this paper
• Receptor expression modulates calcium-sensing receptor mediated intracellular Ca2+ mobilization.

  2015cites this paper
• Cinacalcet and Clinical Outcomes in Dialysis

  2015influential citation
• Calcium/Phosphate Regulation: A Control Engineering Approach

  2014cites this paper
• Calcimimetic agents in the management of secondary hyperparathyroidism among patients with end-stage renal disease; a review article

  2014influential citation
• Calcium-sensing receptor activation in chronic kidney disease: effects beyond parathyroid hormone control.

  2014cites this paper
• Cinacalcet Upregulates Calcium-Sensing Receptors of Parathyroid Glands in Hemodialysis Patients

  2013cites this paper
• Calcimimetics and outcomes in CKD

  2013cites this paper
• Calcium sensing receptor signalling in physiology and cancer.

  2013cites this paper
• Effects of cinacalcet on bone mineral density and bone markers in hemodialysis patients with secondary hyperparathyroidism

  2013cites this paper
• A new concept for the pathogenesis of secondary hyperparathyroidism : Pharmacological validation of the trade-off hypothesis and involvement of FGF 23 / Klotho

  2013cites this paper
• 二次性副甲状腺機能亢進症発症機序の新たな考え方: trade-off仮説の薬理学的検証ならびにFGF23/Klothoの関与

  2013cites this paper
• Significance of the anti-aging protein Klotho

  2013cites this paper
• Medical and Surgical Management (Including Diet)

  2012cites this paper
• Differential gene expression by oxyphil and chief cells of human parathyroid glands.

  2012cites this paper
• The calcium-sensing receptor as a regulator of cellular fate in normal and pathological conditions.

  2012cites this paper
• THE SIGNIFICANCE OF CINACALCET IN CORRECTION OF PHOSPHORUS-CALCIUM DISBALANCE IN PATENTS WITH CHRONIC KIDNEY DISEASE

  2012cites this paper
• Lanthanum chloride bidirectionally influences calcification in bovine vascular smooth muscle cells

  2012cites this paper
• Minireview: the intimate link between calcium sensing receptor trafficking and signaling: implications for disorders of calcium homeostasis.

  2012cites this paper
• Number of enlarged parathyroid glands might be a predictor of cinacalcet response in advanced secondary hyperparathyroidism

  2012cites this paper
• New Concepts for Primary and Secondary Hyperparathyroidism

  2012cites this paper
• Effectiveness of cinacalcet in patients with recurrent/persistent secondary hyperparathyroidism following parathyroidectomy: results of the ECHO study.

  2011cites this paper
• Cinacalcet HCl Suppresses Cyclin D1 Oncogene-Derived Parathyroid Cell Proliferation in a Murine Model for Primary Hyperparathyroidism

  2011cites this paper
• Effects of Calcimimetic Combined with an Angiotensin-Converting Enzyme Inhibitor on Uremic Cardiomyopathy Progression

  2011cites this paper
• Role of Multifunctional Cell Cycle Modulators in Advanced Secondary Hyperparathyroidism

  2011cites this paper
• Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.

  2011cites this paper
• Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients – Results of the Austrian cohort of the ECHO study

  2011cites this paper
• Treatment of cardiovascular calcification in uremia.

  2011cites this paper
• Diseases of the parathyroid gland in chronic kidney disease

  2011cites this paper
• New insights into the role of calcium-sensing receptor activation.

  2011cites this paper
• Cyclooxygenase 2 promotes parathyroid hyperplasia in ESRD.

  2011cites this paper
• Regulation of stability and trafficking of calcium-sensing receptors by pharmacologic chaperones.

  2011influential citation
• Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism.

  2010influential citation
• Roles of calcium-sensing receptor and vitamin d receptor in the pathophysiology of secondary hyperparathyroidism.

  2010cites this paper
• New therapies: calcimimetics, phosphate binders and vitamin D receptor activators

  2010cites this paper
• Pharmacotherapy and interventional treatments for secondary hyperparathyroidism: current therapy and future challenges

  2010cites this paper
• Association of Nodular Hyperplasia With Resistance to Cinacalcet Therapy for Secondary Hyperparathyroidism in Hemodialysis Patients

  2010cites this paper
• Does the downregulation of the FGF23 signaling pathway in hyperplastic parathyroid glands contribute to refractory secondary hyperparathyroidism in CKD patients?

  2010cites this paper
• Calcium-sensing Receptor Biosynthesis Includes a Cotranslational Conformational Checkpoint and Endoplasmic Reticulum Retention*

  2010cites this paper
• Development of a technique for introduction of an expressed complementary deoxyribonucleic acid into parathyroid cells by direct injection.

  2010cites this paper
• Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells.

  2009cites this paper
• The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats.

  2009influential citation
• Vitamin D–Independent Therapeutic Effects of Extracellular Calcium in a Mouse Model of Adult‐Onset Secondary Hyperparathyroidism

  2009cites this paper
• Novel regulatory aspects of the extracellular Ca2+-sensing receptor, CaR

  2009cites this paper
• The role of calcium , calcitriol and its receptors in parathyroid regulation

  2009cites this paper
• Calcimimetics and bone mineral density in renal transplant patients with persistent secondary hyperparathyroidism.

  2009cites this paper
• Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives.

  2009cites this paper
• Clinical Issues Regarding Cinacalcet Hydrochloride in Japan

  2009cites this paper
• [The role of calcium, calcitriol and their receptors in parathyroid regulation].

  2009cites this paper
• Cinacalcet hydrochloride in chronic kidney disease-mineral bone disorder.

  2009cites this paper
• Management of Mineral and Bone Disorder in Chronic Kidney Disease: Quo Vadis?

  2009cites this paper
• Review article: Risks of coronary artery calcification in chronic kidney disease: Do the same rules apply?

  2009cites this paper
• A calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia.

  2009cites this paper
• Direct upregulation of parathyroid calcium-sensing receptor and vitamin D receptor by calcimimetics in uremic rats.

  2009cites this paper
• Interstitial fibrosis and microvascular disease of the heart in uremia: amelioration by a calcimimetic

  2009cites this paper
• Two cases showing successful suppression of secondary hyperparathyroidism with an extended dosing interval of cinacalcet hydrochloride

  2009cites this paper
• The Role of the Calcium-Sensing Receptor in the Pathophysiology of Secondary Hyperparathyroidism

  2008influential citation
• Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs

  2008influential citation
• Regression of parathyroid hyperplasia by calcimimetics--fact or illusion?

  2008cites this paper
• Calcimimetic R-568 or calcitriol: equally beneficial on progression of renal damage in subtotally nephrectomized rats.

  2008cites this paper
• Drugs acting on the calcium receptor: Calcimimetics and calcilytics

  2008cites this paper
• Calcimimetics for the Treatment of Secondary Hyperparathyroidism in Peritoneal Dialysis Patients

  2008cites this paper
• Secondary hyperparathyroidism disease stabilization following calcimimetic therapy

  2008cites this paper
• Biology of the Extracellular Ca2+-Sensing Receptor

  2008cites this paper
• Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations.

  2008cites this paper
• Secondary Hyperparathyroidism Disease Stabilization Following Calcimimetic Therapy

  2008cites this paper
• Anabolic therapy for osteoporosis: Calcilytics

  2008cites this paper
• New strategies for the treatment of hyperparathyroidism incorporating calcimimetics

  2008cites this paper
• CKD-MBD: impact on management of kidney disease

  2007cites this paper
• Activation of calcium-sensing receptor accelerates apoptosis in hyperplastic parathyroid cells.

  2007cites this paper
• The calcium-sensing receptor: physiology, pathophysiology and CaR-based therapeutics.

  2007cites this paper
• Disease of the Month Metabolic Bone Disease in Chronic Kidney Disease

  2007cites this paper
• Treatment of renal osteodystrophy

  2007cites this paper
• Die renale Osteodystrophie - eine Literaturstudie

  2007cites this paper
• Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism.

  2007cites this paper
• Rescue of Calcium-sensing Receptor Mutants by Allosteric Modulators Reveals a Conformational Checkpoint in Receptor Biogenesis*

  2007cites this paper
• The role of calcimimetics in the treatment of hyperparathyroidism

  2007cites this paper
• Metabolic bone disease in chronic kidney disease.

  2007cites this paper
• Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies.

  2007cites this paper
• The role of calcimimetics in chronic kidney disease

  2006cites this paper
• Therapeutic use of calcimimetics.

  2006cites this paper
• Medical therapy of secondary hyperparathyroidism in chronic kidney disease: old and new drugs

  2006influential citation
• Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels

  2006cites this paper